Kristine Kleivi Sahlberg

  • Researcher PhD
  • +47 22 78 13 79
 

Publications 2019

Dork T, Peterlongo P, Mannermaa A, Bolla MK, Wang Q, Dennis J, Ahearn T, Andrulis IL, Anton-Culver H, Arndt V, Aronson KJ, Augustinsson A, Freeman LEB, Beckmann MW, Beeghly-Fadiel A, Behrens S, Bermisheva M, Blomqvist C, Bogdanova N, Bojesen SE, Brauch H, Brenner H, Burwinkel B, Canzian F, Chan TL et al. (2019)
Two truncating variants in FANCC and breast cancer risk
Sci Rep, 9, 12524

Johansson HJ, Socciarelli F, Vacanti NM, Haugen MH, Zhu Y, Siavelis I, Fernandez-Woodbridge A, Aure MR, Sennblad B, Vesterlund M, Branca RM, Orre LM, Huss M, Fredlund E, Beraki E, Garred O, Boekel J, Sauer T, Zhao W, Nord S, Hoglander EK, Jans DC, Brismar H, Haukaas TH, Bathen TF et al. (2019)
Breast cancer quantitative proteome and proteogenomic landscape
Nat. Commun., 10, 1600

Lindholm EM, Aure MR, Haugen MH, Sahlberg KK, Kristensen VN, Nebdal D, Borresen-Dale AL, Lingjrde OC, Engebraaten O (2019)
miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer
Mol. Oncol., 13 (10), 2278-2296

Publications 2018

Tinholt M, Garred O, Borgen E, Beraki E, Schlichting E, Kristensen V, Sahlberg KK, Iversen N (2018)
Subtype-specific clinical and prognostic relevance of tumor-expressed F5 and regulatory F5 variants in breast cancer: the CoCaV study
J. Thromb. Haemost., 16 (7), 1347-1356

Publications 2017

Aure MR, Vitelli V, Jernstrom S, Kumar S, Krohn M, Due EU, Haukaas TH, Leivonen SK, Vollan HKM, Luders T, Rodland E, Vaske CJ, Zhao W, Moller EK, Nord S, Giskeodegard GF, Bathen TF, Caldas C, Tramm T, Alsner J, Overgaard J, Geisler J, Bukholm IRK, Naume B, Schlichting E et al. (2017)
Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome
Breast Cancer Res., 19, 44

Cui XY, Skretting G, Tinholt M, Stavik B, Dahm AEA, Sahlberg KK, Kanse S, Iversen N, Sandset PM (2017)
A novel hypoxia response element regulates oxygen-related repression of tissue factor pathway inhibitor in the breast cancer cell line MCF-7
Thromb. Res., 157, 111-116

Fleischer T, Tekpli X, Mathelier A, Wang SX, Nebdal D, Dhakal HP, Sahlberg KK, Schlichting E, Borresen-Dale AL, Borgen E, Naume B, Eskeland R, Frigessi A, Tost J, Hurtado A, Kristensen VN, Oslo Breast Canc Res Consortium OS (2017)
DNA methylation at enhancers identifies distinct breast cancer lineages
Nat. Commun., 8, 1379

Jernstrom S, Hongisto V, Leivonen SK, Due EU, Tadele DS, Edgren H, Kallioniemi O, Perala M, Mlandsmo GM, Sahlberg KK (2017)
Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response
Breast Cancer-Targets Ther., 9, 185-198

Publications 2016

Cui XY, Tinholt M, Stavik B, Dahm AEA, Kanse S, Jin Y, Seidl S, Sahlberg KK, Iversen N, Skretting G, Sandset PM (2016)
Effect of hypoxia on tissue factor pathway inhibitor expression in breast cancer
J. Thromb. Haemost., 14 (2), 387-396

Haukaas TH, Euceda LR, Giskeodegard GF, Lamichhane S, Krohn M, Jernstrom S, Aure MR, Lingjaerde OC, Schlichting E, Garred O, Due EU, Mills GB, Sahlberg KK, Borresen-Dale AL, Bathen TF, Oslo Breast Canc Consortium (2016)
Metabolic clusters of breast cancer in relation to gene- and protein expression subtypes
Cancer Metab., 4, UNSP 12

Nunes-Xavier CE, Karlsen KF, Tekle C, Pedersen C, Oyjord T, Hongisto V, Nesland JM, Tan M, Sahlberg KK, Fodstad O (2016)
Decreased expression of B7-H3 reduces the glycolytic capacity and sensitizes breast cancer cells to AKT/mTOR inhibitors
Oncotarget, 7 (6), 6891-6901

Tinholt M, Sandset PM, Mowinckel MC, Garred O, Sahlberg KK, Kristensen VN, Borresen-Dale AL, Jacobsen AF, Skretting G, Iversen N (2016)
Determinants of acquired activated protein C resistance and D-dimer in breast cancer
Thromb. Res., 145, 78-83

Publications 2015

Aure MR, Jernstrom S, Krohn M, Vollan HKM, Due EU, Rodland E, Karesen R, Ram P, Lu YL, Mills GB, Sahlberg KK, Borresen-Dale AL, Lingjaerde OC, Kristensen VN, Oslo Breast Canc Res Consortium (2015)
Integrated analysis reveals microRNA networks coordinately expressed with key proteins in breast cancer
Genome Med., 7, 21

Tinholt M, Vollan HKM, Sahlberg KK, Jernstrom S, Kaveh F, Lingjaerde OC, Karesen R, Sauer T, Kristensen V, Borresen-Dale AL, Sandset PM, Iversen N (2015)
Tumor expression, plasma levels and genetic polymorphisms of the coagulation inhibitor TFPI are associated with clinicopathological parameters and survival in breast cancer, in contrast to the coagulation initiator TF
Breast Cancer Res., 17, 44

Publications 2014

Kleivi Sahlberg K, Bottai G, Naume B, Burwinkel B, Calin GA, Børresen-Dale AL, Santarpia L (2014)
A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients
Clin Cancer Res, 21 (5), 1207-14
DOI 10.1158/1078-0432.CCR-14-2011, PubMed 25547678

Nygren MK, Tekle C, Ingebrigtsen VA, Mäkelä R, Krohn M, Aure MR, Nunes-Xavier CE, Perälä M, Tramm T, Alsner J, Overgaard J, Nesland JM, Borgen E, Børresen-Dale AL, Fodstad Ø, Sahlberg KK, Leivonen SK (2014)
Identifying microRNAs regulating B7-H3 in breast cancer: the clinical impact of microRNA-29c
Br J Cancer, 110 (8), 2072-80
DOI 10.1038/bjc.2014.113, PubMed 24577056

Tinholt M, Viken MK, Dahm AE, Vollan HK, Sahlberg KK, Garred O, Børresen-Dale AL, Jacobsen AF, Kristensen V, Bukholm I, Kåresen R, Schlichting E, Skretting G, Lie BA, Sandset PM, Iversen N (2014)
Increased coagulation activity and genetic polymorphisms in the F5, F10 and EPCR genes are associated with breast cancer: a case-control study
BMC Cancer, 14, 845
DOI 10.1186/1471-2407-14-845, PubMed 25407022

Publications 2013

Aure MR, Leivonen SK, Fleischer T, Zhu Q, Overgaard J, Alsner J, Tramm T, Louhimo R, Alnæs GI, Perälä M, Busato F, Touleimat N, Tost J, Børresen-Dale AL, Hautaniemi S, Troyanskaya OG, Lingjærde OC, Sahlberg KK, Kristensen VN (2013)
Individual and combined effects of DNA methylation and copy number alterations on miRNA expression in breast tumors
Genome Biol, 14 (11), R126
DOI 10.1186/gb-2013-14-11-r126, PubMed 24257477

Aure MR, Steinfeld I, Baumbusch LO, Liestøl K, Lipson D, Nyberg S, Naume B, Sahlberg KK, Kristensen VN, Børresen-Dale AL, Lingjærde OC, Yakhini Z (2013)
Identifying in-trans process associated genes in breast cancer by integrated analysis of copy number and expression data
PLoS One, 8 (1), e53014
DOI 10.1371/journal.pone.0053014, PubMed 23382830

Hongisto V, Jernström S, Fey V, Mpindi JP, Kleivi Sahlberg K, Kallioniemi O, Perälä M (2013)
High-throughput 3D screening reveals differences in drug sensitivities between culture models of JIMT1 breast cancer cells
PLoS One, 8 (10), e77232
DOI 10.1371/journal.pone.0077232, PubMed 24194875

Leivonen SK, Sahlberg KK, Mäkelä R, Due EU, Kallioniemi O, Børresen-Dale AL, Perälä M (2013)
High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth
Mol Oncol, 8 (1), 93-104
DOI 10.1016/j.molonc.2013.10.001, PubMed 24148764

Tahiri A, Leivonen SK, Lüders T, Steinfeld I, Ragle Aure M, Geisler J, Mäkelä R, Nord S, Riis ML, Yakhini Z, Kleivi Sahlberg K, Børresen-Dale AL, Perälä M, Bukholm IR, Kristensen VN (2013)
Deregulation of cancer-related miRNAs is a common event in both benign and malignant human breast tumors
Carcinogenesis, 35 (1), 76-85
DOI 10.1093/carcin/bgt333, PubMed 24104550

Publications 2012

Sahlberg KK, Hongisto V, Edgren H, Mäkelä R, Hellström K, Due EU, Moen Vollan HK, Sahlberg N, Wolf M, Børresen-Dale AL, Perälä M, Kallioniemi O (2012)
The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells
Mol Oncol, 7 (3), 392-401
DOI 10.1016/j.molonc.2012.10.012, PubMed 23253899

Publications 2011

Edgren H, Murumagi A, Kangaspeska S, Nicorici D, Hongisto V, Kleivi K, Rye IH, Nyberg S, Wolf M, Borresen-Dale AL, Kallioniemi O (2011)
Identification of fusion genes in breast cancer by paired-end RNA-sequencing
Genome Biol, 12 (1), R6
DOI 10.1186/gb-2011-12-1-r6, PubMed 21247443

Enerly E, Steinfeld I, Kleivi K, Leivonen SK, Aure MR, Russnes HG, Rønneberg JA, Johnsen H, Navon R, Rødland E, Mäkelä R, Naume B, Perälä M, Kallioniemi O, Kristensen VN, Yakhini Z, Børresen-Dale AL (2011)
miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors
PLoS One, 6 (2), e16915
DOI 10.1371/journal.pone.0016915, PubMed 21364938

Westbury CB, Sahlberg KK, Borresen-Dale AL, Isacke CM, Yarnold JR (2011)
Gene expression profiling of human dermal fibroblasts exposed to bleomycin sulphate does not differentiate between radiation sensitive and control patients
Radiat Oncol, 6, 42
DOI 10.1186/1748-717X-6-42, PubMed 21521514

Publications 2010

Muggerud AA, Hallett M, Johnsen H, Kleivi K, Zhou W, Tahmasebpoor S, Amini RM, Botling J, Børresen-Dale AL, Sørlie T, Wärnberg F (2010)
Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer
Mol Oncol, 4 (4), 357-68
DOI 10.1016/j.molonc.2010.06.007, PubMed 20663721

Rantala JK, Edgren H, Lehtinen L, Wolf M, Kleivi K, Vollan HK, Aaltola AR, Laasola P, Kilpinen S, Saviranta P, Iljin K, Kallioniemi O (2010)
Integrative functional genomics analysis of sustained polyploidy phenotypes in breast cancer cells identifies an oncogenic profile for GINS2
Neoplasia, 12 (11), 877-88
DOI 10.1593/neo.10548, PubMed 21082043

Publications 2009

Leivonen SK, Mäkelä R, Ostling P, Kohonen P, Haapa-Paananen S, Kleivi K, Enerly E, Aakula A, Hellström K, Sahlberg N, Kristensen VN, Børresen-Dale AL, Saviranta P, Perälä M, Kallioniemi O (2009)
Protein lysate microarray analysis to identify microRNAs regulating estrogen receptor signaling in breast cancer cell lines
Oncogene, 28 (44), 3926-36
DOI 10.1038/onc.2009.241, PubMed 19684618

Muggerud AA, Edgren H, Wolf M, Kleivi K, Dejeux E, Tost J, Sørlie T, Kallioniemi O (2009)
Data integration from two microarray platforms identifies bi-allelic genetic inactivation of RIC8A in a breast cancer cell line
BMC Med Genomics, 2, 26
DOI 10.1186/1755-8794-2-26, PubMed 19432969

Publications 2007

Kleivi K, Lind GE, Diep CB, Meling GI, Brandal LT, Nesland JM, Myklebost O, Rognum TO, Giercksky KE, Skotheim RI, Lothe RA (2007)
Gene expression profiles of primary colorectal carcinomas, liver metastases, and carcinomatoses
Mol Cancer, 6, 2
DOI 10.1186/1476-4598-6-2, PubMed 17201907

Publications 2006

Diep CB, Kleivi K, Ribeiro FR, Teixeira MR, Lindgjaerde OC, Lothe RA (2006)
The order of genetic events associated with colorectal cancer progression inferred from meta-analysis of copy number changes
Genes Chromosomes Cancer, 45 (1), 31-41
DOI 10.1002/gcc.20261, PubMed 16145679

Kleivi K (2006)
Advances in the genetics and epigenetics of gene regulation and human disease
Genome Biol, 7 (8), 325
DOI 10.1186/gb-2006-7-8-325, PubMed 16934107

Lind GE, Kleivi K, Meling GI, Teixeira MR, Thiis-Evensen E, Rognum TO, Lothe RA (2006)
ADAMTS1, CRABP1, and NR3C1 identified as epigenetically deregulated genes in colorectal tumorigenesis
Cell Oncol, 28 (5-6), 259-72
PubMed 17167179

Publications 2005

Kleivi K, Diep CB, Pandis N, Heim S, Teixeira MR, Lothe RA (2005)
TP53 mutations are associated with a particular pattern of genomic imbalances in breast carcinomas
J Pathol, 207 (1), 14-9
DOI 10.1002/path.1812, PubMed 16007576

Publications 2004

Kleivi K, Teixeira MR, Eknaes M, Diep CB, Jakobsen KS, Hamelin R, Lothe RA (2004)
Genome signatures of colon carcinoma cell lines
Cancer Genet Cytogenet, 155 (2), 119-31
DOI 10.1016/j.cancergencyto.2004.03.014, PubMed 15571797

Publications 2002

Kleivi K, Lothe RA, Heim S, Tsarouha H, Kraggerud SM, Pandis N, Papadopoulou A, Andersen J, Jakobsen KS, Teixeira MR (2002)
Genome profiling of breast cancer cells selected against in vitro shows copy number changes
Genes Chromosomes Cancer, 33 (3), 304-9
DOI 10.1002/gcc.10032, PubMed 11807988

Page visits: 9795